Drug Trial Radar · NCT07192939
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis
Last checked: Nov 20, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Oct 29, 2025
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of HRS-9813 in subjects with pulmonary fibrosis。
Conditions
- IPF and PPF
Interventions
HRS-9813 capsulesDrug
HRS-9813 capsule; High dose
HRS-9813 capsulesDrug
HRS-9813 capsule; Low dose
HRS-9813 capsule mimeticDrug
HRS-9813 capsule mimetic
Primary outcomes
What the sponsor says the trial is designed to measure.
- FVC as a percentage of the predicted valueTime frame: The baseline period lasted until 26weeks after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.